Piper Sandler initiated coverage of RxSight (RXST) with a Neutral rating and $18 price target The firm likes the company’s novel light ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.5, a high estimate of $66.00, and a low estimate of $17.00. Experiencing a 18.74% decline, ...

RxSight faces revenue decline and rising competition in the IOL market. Click here to find out why I am neutral on RXST stock.

CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL ... to highlight the benefits of RxSight’s adjustable IOL platform.

Q1 2025 Management View CEO Dr. Ron Kurtz highlighted that Q1 2025 revenue was impacted by a weakened premium intraocular lens (IOL) market, disruptions from sequential product launches by competitors ...

RxSight (NASDAQ:RXST), a maker of light-adjustable intraocular lenses, fell ~28% in the premarket on Thursday after the company slashed its full-year guidance and announced lower-than-expected ...

RxSight projects the sale of 27,579 Light Adjustable Lenses (LAL/LAL+), with a growth of 36%Y/Y increase in procedure volume. Also, the company anticipates the sale of 73 Light Delivery Devices ...

April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device ... The sale of 27,579 Light Adjustable Lenses (LAL™/LAL+ ®); representing a 36% increase in procedure ...